Genetic Information
Gene & Transcript Details
| ID | Status | Details |
|---|---|---|
| NM_000314.8 | MANE Select | 8515 nt | 846–2057 |
| NM_000314.7 | RefSeq Select | 8514 nt | 845–2056 |
| NM_000314.5 | Alternative | 8719 nt | 1032–2243 |
| NM_000314.4 | Alternative | 5572 nt | 1032–2243 |
| NM_000314.3 | Alternative | 3416 nt | 1032–2243 |
| NM_000314.6 | Alternative | 8718 nt | 1032–2243 |
Variant Details
Clinical & Population Data
Population Frequency
gnomADClinVar
Open"This variant has been reported in ClinVar as Uncertain significance (1 clinical laboratories)."
COSMIC Somatic Evidence
Open
Functional Impact & Domains
Functional Domain
Computational Analysis
Pathogenicity Predictions
SpliceAISpliceAI Scores
Window: ±500bp| Effect Type | Score | Position |
|---|---|---|
| Acceptor Loss (AL) | 0.03 | -185 bp |
| Donor Loss (DL) | 0.0 | -316 bp |
| Acceptor Gain (AG) | 0.01 | 1 bp |
| Donor Gain (DG) | 0.0 | -51 bp |
VCEP Guidelines
Applied ACMG/AMP Criteria (VCEP Specific)
PVS1 (Not Applied)
According to VCEP guidelines, PVS1 applies to null variants in a gene where loss of function is a known mechanism. This variant is missense (H141D), not a null variant. Therefore, this criterion is not applied because the variant type is not a loss-of-function variant.
PS1 (Not Applied)
According to VCEP guidelines, PS1 applies when a variant results in the same amino acid change as a previously established pathogenic variant. This variant (H141D) does not match any known pathogenic codon change at the nucleotide level. Therefore, this criterion is not applied.
PS2 (Not Applied)
According to standard ACMG guidelines, PS2 applies to confirmed de novo observations with paternity and maternity confirmed. No such data are available for this variant. Therefore, this criterion is not applied.
PS3 (Moderate)
According to PTEN Pre-processing guidelines, the rule/finding for PS3 is: "PS3_Moderate evidence added based on high-confidence functional score (-1.4006) < threshold (-1.11)". The evidence for this variant shows a phosphatase activity score of -1.4006, which is below the threshold of -1.11 per Mighell et al. 2018. Therefore, this criterion is applied at Moderate strength because the functional assay result meets the PTEN-specific threshold for damaging effect.
PS4 (Not Applied)
According to VCEP guidelines, PS4 applies when the variant prevalence is significantly increased in affected individuals compared to controls. No case-control or proband data are available for this variant. Therefore, this criterion is not applied.
PM1 (Not Applied)
According to VCEP guidelines, PM1 applies when the variant is located in a critical functional domain (e.g., catalytic motifs 90-94, 123-130, 166-168). H141 is not within these motifs. Therefore, this criterion is not applied.
PM2 (Supporting)
According to VCEP guidelines, the rule for PM2 is: "Supporting Absent in population Databases present at <0.00001 (0.001%) allele frequency in gnomAD or another large sequenced population...". The evidence for this variant shows it is absent from gnomAD (MAF=0%). Therefore, this criterion is applied at Supporting strength because the variant is not present in large population databases.
PM3 (Not Applied)
According to standard ACMG guidelines, PM3 applies to variants observed in trans with a pathogenic variant in a recessive disorder. PTEN-related disorders are autosomal dominant and no trans observations are relevant. Therefore, this criterion is not applied.
PM4 (Not Applied)
According to standard ACMG guidelines, PM4 applies to in-frame insertions/deletions. This variant is a missense substitution. Therefore, this criterion is not applied.
PM5 (Moderate)
According to VCEP guidelines, the rule for PM5 is: "Moderate Missense change at an amino acid residue where a different missense change determined to be pathogenic or likely pathogenic has been seen before. In addition, variant being interrogated must have BLOSUM62 score equal to or less than the known variant." The evidence for this variant shows that H141 is a residue at which a different missense change has been classified as pathogenic and the BLOSUM62 score criterion is met. Therefore, this criterion is applied at Moderate strength.
PM6 (Not Applied)
According to standard ACMG guidelines, PM6 applies to assumed de novo variants without confirmation. No de novo evidence is available. Therefore, this criterion is not applied.
PP1 (Not Applied)
According to VCEP guidelines, PP1 applies when there is co-segregation with disease in multiple affected family members. No segregation data are available. Therefore, this criterion is not applied.
PP2 (Not Applied)
According to standard ACMG guidelines, PP2 applies when missense variants are a common mechanism in a gene with low benign variation rate. PTEN has a range of missense variants, and specific applicability is not established. Therefore, this criterion is not applied.
PP3 (Supporting)
According to VCEP guidelines, the rule for PP3 is: "Supporting Multiple lines of computational evidence support a deleterious effect on the gene or gene product. Missense variants: REVEL score > 0.7." The evidence for this variant shows a REVEL score of 0.84, exceeding the threshold of 0.7. Therefore, this criterion is applied at Supporting strength because multiple in silico tools predict a damaging effect.
PP4 (Not Applied)
According to standard ACMG guidelines, PP4 applies when a patient’s phenotype is highly specific for a disease with a single genetic etiology. No phenotype data are provided. Therefore, this criterion is not applied.
PP5 (Not Applied)
According to standard ACMG guidelines, PP5 applies when a reputable source reports a variant as pathogenic. ClinVar lists this variant as VUS. Therefore, this criterion is not applied.
BA1 (Not Applied)
According to VCEP guidelines, BA1 applies when allele frequency >0.056% in gnomAD. This variant is absent. Therefore, this criterion is not applied.
BS1 (Not Applied)
According to VCEP guidelines, BS1 applies when allele frequency is between 0.0043% and 0.056% in gnomAD. This variant is absent. Therefore, this criterion is not applied.
BS2 (Not Applied)
According to VCEP guidelines, BS2 applies when a variant is observed in homozygous state in healthy individuals. No such observations exist. Therefore, this criterion is not applied.
BS3 (Not Applied)
According to VCEP guidelines, BS3 applies when functional studies show no damaging effect. Functional data show a damaging effect (PS3). Therefore, this criterion is not applied.
BS4 (Not Applied)
According to VCEP guidelines, BS4 applies when there is lack of segregation in multiple families. No segregation data are available. Therefore, this criterion is not applied.
BP1 (Not Applied)
According to standard ACMG guidelines, BP1 applies when missense variants in a gene where only truncating variants cause disease. PTEN disease mechanism includes missense. Therefore, this criterion is not applied.
BP2 (Not Applied)
According to VCEP guidelines, BP2 applies when variant is observed in trans with a pathogenic variant. Not applicable. Therefore, this criterion is not applied.
BP3 (Not Applied)
According to standard ACMG guidelines, BP3 applies to in-frame indels in repetitive regions. This variant is missense. Therefore, this criterion is not applied.
BP4 (Not Applied)
According to VCEP guidelines, BP4 applies when computational evidence suggests no impact (REVEL <0.5). The REVEL score is 0.84, indicating impact. Therefore, this criterion is not applied.
BP5 (Not Applied)
According to standard ACMG guidelines, BP5 applies when a variant is found in a case with an alternate molecular basis for disease. No alternate diagnosis data are provided. Therefore, this criterion is not applied.
BP6 (Not Applied)
According to standard ACMG guidelines, BP6 applies when a reputable source reports a variant as benign. ClinVar reports this variant as VUS. Therefore, this criterion is not applied.
BP7 (Not Applied)
According to VCEP guidelines, BP7 applies to synonymous or intronic variants with no splicing impact. This variant is missense. Therefore, this criterion is not applied.